Clinical trials: Cardiovascular Disease Acute
Stroke, Stroke, Acute Ischemic
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard…
- Conditions
- Stroke, Stroke, Acute Ischemic, Stroke, Ischemic, Stroke, Cryptogenic
- Trial name
- NAiD-PRO (NCT07828210)
- Testing
- MLC901, Standard treatment for acute ischemic stroke
- Where
- Vietnam
- Volunteers
- 80 people
- Sponsor
- EVD Pharmacy and Medical Company Limited
Myocardial Infarction
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community…
- Trial name
- NCT00623623
- Testing
- primary PCI, enoxaparin, catheterisation
- Where
- 201 sites in Austria, Belgium and 14 more
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease, Atherosclerosis
Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT
OBJECTIVE It is the objective of the REMEDEE OCT study to assess vascular healing after deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) in patients with Acute…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Acute Coronary Syndrome (ACS), Myocardial Infarction (MI)
- Trial name
- REMEDEE-OCT (NCT01405287)
- Testing
- PTCA with stent placement
- Where
- 6 sites in Belgium, Finland and 3 more
- Volunteers
- 60 people
- Sponsor
- OrbusNeich
Acute Ischemic Stroke (AIS)
Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke
- Trial name
- ARPEGGIO (NCT05585606)
- Testing
- scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg)
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- Silver Creek Pharmaceuticals
Heart Failure, Congestive, Heart Decompensation
Registry for Acute Decompensated Heart Failure Patients Admitted to the ER
The purpose of this study is to collect data on the medical management of patients presenting to the Emergency Department who are treated for Acute Decompensated Heart Failure (ADHF) in a hospital setting that has incorporated a…
- Trial name
- NCT00364325
- Testing
- Acute Decompensated Heart Failure
- Volunteers
- 18,920 people
- Sponsor
- Scios, Inc.
Ischemic Stroke
A Study of NCS-01 in Patients With Acute Ischemic Stroke
This is an initial Phase1/2 dose-finding, randomized, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 48 hours of stroke onset.
- Trial name
- NCT03915431
- Testing
- NCS-01
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NC Medial Research Inc
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
- Trial name
- NCT01064505
- Testing
- QPI-1007 at various doses
- Where
- 28 sites in United States, Israel
- Volunteers
- 48 people
- Sponsor
- Quark Pharmaceuticals
Acute Ischemic Stroke
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
- Trial name
- BRIGHT (NCT05403866)
- Testing
- LT3001 Drug Product
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Cerebral Infarction
The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction
The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).
- Trial name
- NCT03186456
- Testing
- Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), Aspirin Tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
This is a non-randomised, open-label phase I study of an investigational medicinal product (IMP) consisting of a HLA-A*02:01 restricted HA-1H T cell receptor transduced T cell (MDG1021) immunotherapy for relapsed or persistent…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
- Trial name
- NCT04464889
- Testing
- MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3
- Where
- Netherlands
- Sponsor
- Medigene AG
Emphysema, Acute Respiratory Distress Syndrome
Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
A new artificial lung device has been developed that potentially provides added support to mechanical ventilation for severely damaged lungs.
- Conditions
- Emphysema, Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00288964
- Testing
- Hattler Respiratory Assist Catheter
- Where
- United Kingdom
- Sponsor
- Alung Technologies
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system…
- Trial name
- NEUTRALIZE-CRS (NCT03836482)
- Testing
- Selective Cytopheretic Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SeaStar Medical
Central Retinal Artery Occlusion
A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)
Central retinal artery occlusion (CRAO) is an ophthalmologic emergency which leads to severe and permanent vision loss. There is no evidence-based therapy for CRAO.
- Trial name
- GION (NCT06178055)
- Testing
- KUS121 high dose, KUS121 low dose
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kyoto Drug Discovery and Development Co., Ltd.
Congestive Heart Failure
Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667
The purpose of this study is to assess a dose titration scheme, of a new drug (BAY58-2667) given intravenously, to evaluate if this is safe and can help to improve the well-being, symptoms (e.g.
- Trial name
- NCT00559650
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 72 sites in United States, Canada and 15 more
- Volunteers
- 150 people
- Sponsor
- Bayer
Coronary Artery Disease
Rise Semi Compliant Balloon Study in Patient With CAD
Single arm, prospective, multi-center, trial designed to enrol approximately 66 patients. All patients will undergo PCI using at least one RISE SC balloon as per routine clinical practice and will be followed until discharge for…
- Trial name
- NCT04796038
- Testing
- Balloon dilatation
- Where
- 3 sites in Switzerland
- Volunteers
- 67 people
- Sponsor
- Biosensors Europe SA
Acute Ischemic Stroke
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
Overall Design: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-exploration study. Main outcome: 1.To evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke.
- Trial name
- XY03-EA (NCT05515393)
- Testing
- XY03-EA
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Wound
Evaluation of the Safety and Effectiveness of ALLEVYN Gentle Border
The clinical study will evaluate the safety and effectiveness of the ALLEVYN Gentle Border. The study is a post-market clinical follow-up to assess clinical performance and safety of ALLEVYN Gentle Border with new wound contact…
- Trial name
- NCT03877484
- Testing
- ALLEVYN Gentle border
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Smith & Nephew Orthopaedics AG
Solid Tumors
Study of INCB053914 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation study of the proviral integration site of Moloney murine leukemia virus (PIM) kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 4 parts.
- Trial name
- NCT02587598
- Testing
- INCB053914, I-DAC (Intermediate dose cytarabine), Azacitidine
- Where
- 19 sites in United States
- Volunteers
- 97 people
- Sponsor
- Incyte Corporation
Cerebrovascular Accident
EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
German stroke units are hesitating to use Aggrenox for secondary ischaemic stroke / transient ischaemic attack (TIA) prevention in a sub-acute treatment setting.
- Trial name
- NCT00562588
- Testing
- Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg), ASA 100 mg qd
- Where
- Germany
- Volunteers
- 551 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
SY007 in Patients With Acute Ischemic Stroke
This Phase 1b multiple center, randomized, double-blind, placebo-controlled study is a dose escalation trial evaluating the safety, tolerability, PK characteristics and efficacy of SY-007 after injection in acute ischemicstroke…
- Trial name
- NCT04891913
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.